biostudies-literatureSiddiqi TJuno TherapeuticsBristol-Myers SquibbNCI NIH HHS641-654https://www.ebi.ac.uk/biostudies/studies/S-EPMC11753452biostudies-literatureUnknown402(10402)<h4>Background</h4>Patients with relapsed or refractory chronic lymphocytic leukaemia or small lymphocytic lymphoma for whom treatment has failed with both Bruton tyrosine kinase (BTK) inhibitor and venetoclax have few treatment options and poor outcomes. We aimed to evaluate the efficacy and safety of lisocabtagene maraleucel (liso-cel) at the recommended phase 2 dose in patients with relapsed or refractory chronic lymphocytic leukaemia or small lymphocytic lymphoma.<h4>Methods</h4>We report the primary analysis of TRANSCEND CLL 004, an open-label, single-arm, phase 1-2 study conducted in the USA. Patients aged 18 years or older with relapsed or refractory chronic lymphocytic leukaemia or small lymphocytic lymphoma and at least two previous lines of therapy, including a BTK inhibitor, recLancet (London, England)Lisocabtagene maraleucel in chronic lymphocytic leukaemia and small lymphocytic lymphoma (TRANSCEND CLL 004): a multicentre, open-label, single-arm, phase 1-2 study.PMC11753452P30 CA016672Ma SSiddiqi TKenderian SSBrander DMFakhri BDorritie KShah NNSoumerai JSchuster SJMaloney DGTuazon SAStephens DMSolomon SROu SSFeldman TRiedell PAPapp EChen YPeiser LWierda WGNath RPerna SKfalseLisocabtagene maraleucel in chronic lymphocytic leukaemia and small lymphocytic lymphoma (TRANSCEND CLL 004): a multicentre, open-label, single-arm, phase 1-2 study.<h4>Background</h4>Patients with relapsed or refractory chronic lymphocytic leukaemia or small lymphocytic lymphoma for whom treatment has failed with both Bruton tyrosine kinase (BTK) inhibitor and venetoclax have few treatment options and poor outcomes. We aimed to evaluate the efficacy and safety of lisocabtagene maraleucel (liso-cel) at the recommended phase 2 dose in patients with relapsed or refractory chronic lymphocytic leukaemia or small lymphocytic lymphoma.<h4>Methods</h4>We report the primary analysis of TRANSCEND CLL 004, an open-label, single-arm, phase 1-2 study conducted in the USA. Patients aged 18 years or older with relapsed or refractory chronic lymphocytic leukaemia or small lymphocytic lymphoma and at least two previous lines of therapy, including a BTK inhibitor, rec2023-01-01T00:00:00Z2023 Aug2026-06-01T18:05:08.445Z2025-04-04T22:06:52.497ZS-EPMC117534523729544510.1016/S0140-6736(23)01052-810.1016/s0140-6736(23)01052-8